CytomX Shares Surge 44% on Phase 1 Tumor Shrinkage Data
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- CytomX Therapeutics closed at $6.75, up 44.23%, after releasing Phase 1 Varseta‑M data in metastatic colorectal cancer.
- Trading volume surged to 118 million shares, roughly 2,211% above its three‑month average of 5.1 million.
- Phase 1 data for varsetatug masetecan (Varseta‑M) reported an objective response rate of up to 32% and a median progression‑free survival of about seven months.
- CytomX plans to discuss FDA registrational trial pathways in 2026 based on the Phase 1 results.
- Financials showed 2025 revenue around $76 million, a net loss wider than forecast, and cash of about $137 million, enough to fund operations into the second quarter of 2027.
Why it matters: Investors enjoy a rapid share price boost as the 32% tumor response fuels optimism, yet CytomX’s net loss and a $137 million cash runway only extending to Q2 2027 underscore financial risk if later‑stage data or FDA talks stall for shareholders.
Ask SkimNews
